| abstract |
The present invention provides N-((heteroaryl)methyl)-l-toluenesulfonyl-lH-pyrazole-3-carboxamide derivatives of formula (I), which can activate Kv3 potassium channels. A separate aspect of the present invention relates to pharmaceutical compositions comprising said compounds, and to these compounds and pharmaceutical compositions thereof for use in a method of drug treatment of disorders responsive to Kv3 potassium channel activation, such as, for example, neurological or psychiatric disorders , such as epilepsy, schizophrenia, cognitive impairment associated with schizophrenia (CIAS), autism spectrum disorder, bipolar disorder, ADHD, anxiety-related disorders, depression, cognitive impairment, Alzheimer's disease, Fragile X syndrome, chronic pain, hearing loss, sleep and circadian rhythm disturbances, and sleep disruption. Exemplary compounds are, for example: 4-methyl-N-((5-methylpyrazin-2-yl)methyl)-1-toluenesulfonyl-1H-pyrazole-3-carboxamide (Example 1; Compound 32), N-((1-methyl-1H-pyrazole-4-yl)methyl)-1-toluenesulfonyl-1H-pyrazole-3-carboxamide (Example 2; Compound 62), 1-((4-(difluoromethoxy)phenyl)sulfonyl)-N-((5-methylpyrazin-2-yl)methyl)-1H-pyrazole-3-carboxamide ( Example 3; Compound 65). The present specification discloses the synthesis of exemplary compounds and associated biological activity data (eg, pages 24-47; Examples 1-3; Table 1; Compounds 1-86). |